---
document_datetime: 2025-12-02 05:50:44
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/lumykras.html
document_name: lumykras.html
version: success
processing_time: 0.1093727
conversion_datetime: 2025-12-28 13:46:44.154658
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Lumykras

[RSS](/en/individual-human-medicine.xml/67508)

##### Authorised

This medicine is authorised for use in the European Union

sotorasib Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Lumykras](#news-on)
- [More information on Lumykras](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Lumykras is a cancer medicine used to treat adults with non-small cell lung cancer (NSCLC) when the cancer is advanced, and its cells have a particular genetic change. The change is in the gene KRAS and is known as 'KRAS G12C'. Lumykras is given when the disease has progressed after receiving systemic treatment (treatment affecting the whole body).

Lumykras contains the active substance sotorasib.

Expand section

Collapse section

## How is Lumykras used?

The medicine can only be obtained with a prescription, and treatment with Lumykras should be started by a doctor who is experienced in using cancer medicines.

The patient's cancer should be tested before starting treatment to confirm it has the genetic change affecting KRAS (KRAS G12C).

Lumykras is available as tablets and is taken by mouth. The recommended dose is 960 mg once per day. Treatment is continued until the disease gets worse or side effects become too severe.

If certain side effects develop, the doctor may decide to reduce the dose to 480 mg once per day and then, if needed, to 240 mg once per day. Treatment should be stopped if side effects are too great at the lowest dose (240 mg).

For more information about using Lumykras, see the package leaflet or contact your doctor or pharmacist.

## How does Lumykras work?

Genetic changes to the KRAS gene can produce an altered protein that causes the uncontrolled growth of cancer cells. The active substance in Lumykras, sotorasib, attaches to this altered protein inside cancer cells. This blocks the protein from acting, interrupting the chemical messages the cancer cells need for growing and spreading, and it also encourages processes that cause the cancer cells to die.

## What benefits of Lumykras have been shown in studies?

In one main study involving 124 patients, Lumykras was effective in treating adults with NSCLC with the KRAS G12C genetic change whose disease had progressed after previously being treated with other cancer medicines. Lumykras was not compared with any other treatment or placebo (a dummy treatment).

Response to treatment (shrinkage in the size of the cancer) was assessed using body scans. Around 37% (46 out of 124) of the patients showed partial or complete cancer shrinkage after treatment with Lumykras. On average, responses lasted for just over 11 months.

## What are the risks associated with Lumykras?

The most common side effects with Lumykras (which may affect more than 1 in 5 people) are diarrhoea, nausea (feeling sick) and tiredness. The most common severe side effects with Lumykras (which may affect up to 1 in 100 people) are increased levels of certain liver enzymes (a sign of possible liver problems) and liver injury. For the full list of side effects and restrictions of Lumykras, see the package leaflet.

## Why is Lumykras authorised in the EU?

There are currently few treatment options for patients with advanced NSCLC with KRAS G12C mutations for whom the cancer has progressed after systemic treatment with cancer medicines, and current treatments have limited effectiveness. Although the main study did not compare Lumykras with another cancer treatment, it showed that the medicine was effective at treating the cancer including in patients whose cancer had progressed after several different treatments. In general, Lumykras' side effects were considered manageable.

The European Medicines Agency, therefore, decided that Lumykras' benefits are greater than its risks and it can be authorised for use in the EU.

Lumykras has been given 'conditional authorisation'. This means that there is more evidence to come about the medicine, which the company is required to provide. Every year, the European Medicines Agency will review any new information that becomes available and this overview will be updated as necessary.

## What information is still awaited for Lumykras?

Since Lumykras has been given conditional authorisation, the company that markets Lumykras will provide further information from an ongoing study. The study will compare the efficacy and safety of Lumykras in treating previously treated NSCLC with KRAS G12C mutation with those of another cancer medicine, docetaxel.

## What measures are being taken to ensure the safe and effective use of Lumykras?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Lumykras have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Lumykras are continuously monitored. Suspected side effects reported with Lumykras are carefully evaluated and any necessary action taken to protect patients.

## Other information about Lumykras

Lumykras received a conditional marketing authorisation valid throughout the EU on 06 January 2022.

Lumykras : EPAR - Medicine Overview

Reference Number: EMA/685702/2021

English (EN) (136.1 KB - PDF)

**First published:** 31/03/2022

[View](/en/documents/overview/lumykras-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-943)

български (BG) (164.27 KB - PDF)

**First published:**

31/03/2022

[View](/bg/documents/overview/lumykras-epar-medicine-overview_bg.pdf)

español (ES) (132.2 KB - PDF)

**First published:**

31/03/2022

[View](/es/documents/overview/lumykras-epar-medicine-overview_es.pdf)

čeština (CS) (155.61 KB - PDF)

**First published:**

31/03/2022

[View](/cs/documents/overview/lumykras-epar-medicine-overview_cs.pdf)

dansk (DA) (132.71 KB - PDF)

**First published:**

31/03/2022

[View](/da/documents/overview/lumykras-epar-medicine-overview_da.pdf)

Deutsch (DE) (136.13 KB - PDF)

**First published:**

31/03/2022

[View](/de/documents/overview/lumykras-epar-medicine-overview_de.pdf)

eesti keel (ET) (127.13 KB - PDF)

**First published:**

31/03/2022

[View](/et/documents/overview/lumykras-epar-medicine-overview_et.pdf)

ελληνικά (EL) (163.96 KB - PDF)

**First published:**

31/03/2022

[View](/el/documents/overview/lumykras-epar-medicine-overview_el.pdf)

français (FR) (133.65 KB - PDF)

**First published:**

31/03/2022

[View](/fr/documents/overview/lumykras-epar-medicine-overview_fr.pdf)

hrvatski (HR) (154.12 KB - PDF)

**First published:**

31/03/2022

[View](/hr/documents/overview/lumykras-epar-medicine-overview_hr.pdf)

italiano (IT) (131.69 KB - PDF)

**First published:**

31/03/2022

[View](/it/documents/overview/lumykras-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (160.1 KB - PDF)

**First published:**

31/03/2022

[View](/lv/documents/overview/lumykras-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (152.4 KB - PDF)

**First published:**

31/03/2022

[View](/lt/documents/overview/lumykras-epar-medicine-overview_lt.pdf)

magyar (HU) (154.13 KB - PDF)

**First published:**

31/03/2022

[View](/hu/documents/overview/lumykras-epar-medicine-overview_hu.pdf)

Malti (MT) (155.94 KB - PDF)

**First published:**

31/03/2022

[View](/mt/documents/overview/lumykras-epar-medicine-overview_mt.pdf)

Nederlands (NL) (133.53 KB - PDF)

**First published:**

31/03/2022

[View](/nl/documents/overview/lumykras-epar-medicine-overview_nl.pdf)

polski (PL) (156.97 KB - PDF)

**First published:**

31/03/2022

[View](/pl/documents/overview/lumykras-epar-medicine-overview_pl.pdf)

português (PT) (133.16 KB - PDF)

**First published:**

31/03/2022

[View](/pt/documents/overview/lumykras-epar-medicine-overview_pt.pdf)

română (RO) (143.97 KB - PDF)

**First published:**

31/03/2022

[View](/ro/documents/overview/lumykras-epar-medicine-overview_ro.pdf)

slovenčina (SK) (154.19 KB - PDF)

**First published:**

31/03/2022

[View](/sk/documents/overview/lumykras-epar-medicine-overview_sk.pdf)

slovenščina (SL) (153.71 KB - PDF)

**First published:**

31/03/2022

[View](/sl/documents/overview/lumykras-epar-medicine-overview_sl.pdf)

Suomi (FI) (129.23 KB - PDF)

**First published:**

31/03/2022

[View](/fi/documents/overview/lumykras-epar-medicine-overview_fi.pdf)

svenska (SV) (130.92 KB - PDF)

**First published:**

31/03/2022

[View](/sv/documents/overview/lumykras-epar-medicine-overview_sv.pdf)

Lumykras : EPAR - Risk management plan

English (EN) (1.6 MB - PDF)

**First published:** 03/12/2024

[View](/en/documents/rmp-summary/lumykras-epar-risk-management-plan_en.pdf)

## Product information

Lumykras : EPAR - Product Information

English (EN) (328.66 KB - PDF)

**First published:** 31/03/2022

**Last updated:** 03/12/2024

[View](/en/documents/product-information/lumykras-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-890)

български (BG) (503.94 KB - PDF)

**First published:**

31/03/2022

**Last updated:**

03/12/2024

[View](/bg/documents/product-information/lumykras-epar-product-information_bg.pdf)

español (ES) (421.81 KB - PDF)

**First published:**

31/03/2022

**Last updated:**

03/12/2024

[View](/es/documents/product-information/lumykras-epar-product-information_es.pdf)

čeština (CS) (518.19 KB - PDF)

**First published:**

31/03/2022

**Last updated:**

03/12/2024

[View](/cs/documents/product-information/lumykras-epar-product-information_cs.pdf)

dansk (DA) (422.01 KB - PDF)

**First published:**

31/03/2022

**Last updated:**

03/12/2024

[View](/da/documents/product-information/lumykras-epar-product-information_da.pdf)

Deutsch (DE) (434 KB - PDF)

**First published:**

31/03/2022

**Last updated:**

03/12/2024

[View](/de/documents/product-information/lumykras-epar-product-information_de.pdf)

eesti keel (ET) (412.41 KB - PDF)

**First published:**

31/03/2022

**Last updated:**

03/12/2024

[View](/et/documents/product-information/lumykras-epar-product-information_et.pdf)

ελληνικά (EL) (506.86 KB - PDF)

**First published:**

31/03/2022

**Last updated:**

03/12/2024

[View](/el/documents/product-information/lumykras-epar-product-information_el.pdf)

français (FR) (445.19 KB - PDF)

**First published:**

31/03/2022

**Last updated:**

03/12/2024

[View](/fr/documents/product-information/lumykras-epar-product-information_fr.pdf)

hrvatski (HR) (485.92 KB - PDF)

**First published:**

31/03/2022

**Last updated:**

03/12/2024

[View](/hr/documents/product-information/lumykras-epar-product-information_hr.pdf)

íslenska (IS) (408.43 KB - PDF)

**First published:**

31/03/2022

**Last updated:**

03/12/2024

[View](/is/documents/product-information/lumykras-epar-product-information_is.pdf)

italiano (IT) (424.36 KB - PDF)

**First published:**

31/03/2022

**Last updated:**

03/12/2024

[View](/it/documents/product-information/lumykras-epar-product-information_it.pdf)

latviešu valoda (LV) (489.68 KB - PDF)

**First published:**

31/03/2022

**Last updated:**

03/12/2024

[View](/lv/documents/product-information/lumykras-epar-product-information_lv.pdf)

lietuvių kalba (LT) (491.12 KB - PDF)

**First published:**

31/03/2022

**Last updated:**

03/12/2024

[View](/lt/documents/product-information/lumykras-epar-product-information_lt.pdf)

magyar (HU) (500.89 KB - PDF)

**First published:**

31/03/2022

**Last updated:**

03/12/2024

[View](/hu/documents/product-information/lumykras-epar-product-information_hu.pdf)

Malti (MT) (559.72 KB - PDF)

**First published:**

31/03/2022

**Last updated:**

03/12/2024

[View](/mt/documents/product-information/lumykras-epar-product-information_mt.pdf)

Nederlands (NL) (420.61 KB - PDF)

**First published:**

31/03/2022

**Last updated:**

03/12/2024

[View](/nl/documents/product-information/lumykras-epar-product-information_nl.pdf)

norsk (NO) (406.29 KB - PDF)

**First published:**

31/03/2022

**Last updated:**

03/12/2024

[View](/no/documents/product-information/lumykras-epar-product-information_no.pdf)

polski (PL) (498.22 KB - PDF)

**First published:**

31/03/2022

**Last updated:**

03/12/2024

[View](/pl/documents/product-information/lumykras-epar-product-information_pl.pdf)

português (PT) (412.94 KB - PDF)

**First published:**

31/03/2022

**Last updated:**

03/12/2024

[View](/pt/documents/product-information/lumykras-epar-product-information_pt.pdf)

română (RO) (485.9 KB - PDF)

**First published:**

31/03/2022

**Last updated:**

03/12/2024

[View](/ro/documents/product-information/lumykras-epar-product-information_ro.pdf)

slovenčina (SK) (527.68 KB - PDF)

**First published:**

31/03/2022

**Last updated:**

03/12/2024

[View](/sk/documents/product-information/lumykras-epar-product-information_sk.pdf)

slovenščina (SL) (492.86 KB - PDF)

**First published:**

31/03/2022

**Last updated:**

03/12/2024

[View](/sl/documents/product-information/lumykras-epar-product-information_sl.pdf)

Suomi (FI) (417.56 KB - PDF)

**First published:**

31/03/2022

**Last updated:**

03/12/2024

[View](/fi/documents/product-information/lumykras-epar-product-information_fi.pdf)

svenska (SV) (419.39 KB - PDF)

**First published:**

31/03/2022

**Last updated:**

03/12/2024

[View](/sv/documents/product-information/lumykras-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** II/0010/G 21/10/2024

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Lumykras : EPAR - All authorised presentations

English (EN) (96.32 KB - PDF)

**First published:** 31/03/2022

**Last updated:** 03/12/2024

[View](/en/documents/all-authorised-presentations/lumykras-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-179)

български (BG) (59.93 KB - PDF)

**First published:**

31/03/2022

**Last updated:**

03/12/2024

[View](/bg/documents/all-authorised-presentations/lumykras-epar-all-authorised-presentations_bg.pdf)

español (ES) (51.99 KB - PDF)

**First published:**

31/03/2022

**Last updated:**

03/12/2024

[View](/es/documents/all-authorised-presentations/lumykras-epar-all-authorised-presentations_es.pdf)

čeština (CS) (53.84 KB - PDF)

**First published:**

31/03/2022

**Last updated:**

03/12/2024

[View](/cs/documents/all-authorised-presentations/lumykras-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (53.41 KB - PDF)

**First published:**

31/03/2022

**Last updated:**

03/12/2024

[View](/da/documents/all-authorised-presentations/lumykras-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (52.68 KB - PDF)

**First published:**

31/03/2022

**Last updated:**

03/12/2024

[View](/de/documents/all-authorised-presentations/lumykras-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (50.49 KB - PDF)

**First published:**

31/03/2022

**Last updated:**

03/12/2024

[View](/et/documents/all-authorised-presentations/lumykras-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (56.77 KB - PDF)

**First published:**

31/03/2022

**Last updated:**

03/12/2024

[View](/el/documents/all-authorised-presentations/lumykras-epar-all-authorised-presentations_el.pdf)

français (FR) (51.81 KB - PDF)

**First published:**

31/03/2022

**Last updated:**

03/12/2024

[View](/fr/documents/all-authorised-presentations/lumykras-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (53.01 KB - PDF)

**First published:**

31/03/2022

**Last updated:**

03/12/2024

[View](/hr/documents/all-authorised-presentations/lumykras-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (52.97 KB - PDF)

**First published:**

31/03/2022

**Last updated:**

03/12/2024

[View](/is/documents/all-authorised-presentations/lumykras-epar-all-authorised-presentations_is.pdf)

italiano (IT) (52.85 KB - PDF)

**First published:**

31/03/2022

**Last updated:**

03/12/2024

[View](/it/documents/all-authorised-presentations/lumykras-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (55.61 KB - PDF)

**First published:**

31/03/2022

**Last updated:**

03/12/2024

[View](/lv/documents/all-authorised-presentations/lumykras-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (54.39 KB - PDF)

**First published:**

31/03/2022

**Last updated:**

03/12/2024

[View](/lt/documents/all-authorised-presentations/lumykras-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (53.68 KB - PDF)

**First published:**

31/03/2022

**Last updated:**

03/12/2024

[View](/hu/documents/all-authorised-presentations/lumykras-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (56.27 KB - PDF)

**First published:**

31/03/2022

**Last updated:**

03/12/2024

[View](/mt/documents/all-authorised-presentations/lumykras-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (51.44 KB - PDF)

**First published:**

31/03/2022

**Last updated:**

03/12/2024

[View](/nl/documents/all-authorised-presentations/lumykras-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (53.46 KB - PDF)

**First published:**

31/03/2022

**Last updated:**

03/12/2024

[View](/no/documents/all-authorised-presentations/lumykras-epar-all-authorised-presentations_no.pdf)

polski (PL) (55.53 KB - PDF)

**First published:**

31/03/2022

**Last updated:**

03/12/2024

[View](/pl/documents/all-authorised-presentations/lumykras-epar-all-authorised-presentations_pl.pdf)

português (PT) (53.22 KB - PDF)

**First published:**

31/03/2022

**Last updated:**

03/12/2024

[View](/pt/documents/all-authorised-presentations/lumykras-epar-all-authorised-presentations_pt.pdf)

română (RO) (54.25 KB - PDF)

**First published:**

31/03/2022

**Last updated:**

03/12/2024

[View](/ro/documents/all-authorised-presentations/lumykras-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (67.35 KB - PDF)

**First published:**

31/03/2022

**Last updated:**

03/12/2024

[View](/sk/documents/all-authorised-presentations/lumykras-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (55.88 KB - PDF)

**First published:**

31/03/2022

**Last updated:**

03/12/2024

[View](/sl/documents/all-authorised-presentations/lumykras-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (50.94 KB - PDF)

**First published:**

31/03/2022

**Last updated:**

03/12/2024

[View](/fi/documents/all-authorised-presentations/lumykras-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (52 KB - PDF)

**First published:**

31/03/2022

**Last updated:**

03/12/2024

[View](/sv/documents/all-authorised-presentations/lumykras-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Lumykras Active substance sotorasib International non-proprietary name (INN) or common name sotorasib Therapeutic area (MeSH) Carcinoma, Non-Small-Cell Lung Anatomical therapeutic chemical (ATC) code L01XX73

### Pharmacotherapeutic group

Antineoplastic agents

### Therapeutic indication

Lumykras as monotherapy is indicated for the treatment of adults with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and who have progressed after at least one prior line of systemic therapy.

## Authorisation details

EMA product number EMEA/H/C/005522

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Conditional approval

This medicine received a conditional marketing authorisation. This was granted in the interest of public health because the medicine addresses an unmet medical need and the benefit of immediate availability outweighs the risk from less comprehensive data than normally required. For more information, see [Conditional marketing authorisation](/node/68774) .

Marketing authorisation holder

Amgen Europe B.V.

Minervum 7061

Opinion adopted 11/11/2021 Marketing authorisation issued 06/01/2022 Revision 6

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Lumykras : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (164.64 KB - PDF)

**First published:** 29/11/2022

**Last updated:** 03/12/2024

[View](/en/documents/procedural-steps-after/lumykras-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Lumykras : EPAR - Public Assessment Report

Adopted

Reference Number: EMA/706135/2021

English (EN) (5.32 MB - PDF)

**First published:** 31/03/2022

[View](/en/documents/assessment-report/lumykras-epar-public-assessment-report_en.pdf)

CHMP summary of opinion for Lumykras

Adopted

Reference Number: EMA/624008/2021

English (EN) (100.47 KB - PDF)

**First published:** 12/11/2021

[View](/en/documents/smop-initial/chmp-summary-opinion-lumykras_en.pdf)

#### News on Lumykras

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 8-11 November 2021](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-8-11-november-2021) 12/11/2021

#### More information on Lumykras

- [EMEA-002690-PIP02-22 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-002690-pip02-22)
- [Comparative Effectiveness of Sotorasib Versus Docetaxel Monotherapy in Second Line and Beyond (2L+) Among Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) in the Cancer Analysis System Database in England (20240164) - post-authorisation study](https://catalogues.ema.europa.eu/study/1000000405)
- [Observational Study on the Safety and Effectiveness of Sotorasib in South Korea (20200009) - post-authorisation study](https://catalogues.ema.europa.eu/study/105849)
- [Special Drug Use-Results Surveillance (all-case) for sotorasib in patients with KRAS G12C-mutated, unresectable, advanced and/or recurrent non-small-cell lung cancer, that has progressed after systemic anticancer therapy in Japan (20210051) - post-authorisation study](https://catalogues.ema.europa.eu/study/47965)

**This page was last updated on** 03/12/2024

## Share this page

[Back to top](#main-content)